N-SIDE announced an additional investment of over €10 million.
N-SIDE, a Louvain-la-Neuve (Bruxelles), Belgium-based SAAS developer for the pharma industry, announced completing a capital investment round of over €10 million ($11.8M).
The money was raised from existing investors in the company, including Gaëtan Hannecart from Matexi, François le Hodey from IPM, Jacques van Rijkervorsel and Jean Stéphenne, as well as participation from N-SIDE co-founder and president Philippe Chevalier.
Employees of the company were invited into the round, as the company says that 20% of them will participate in the capital. This is an inclusive development for the company, which will have 150 employees worldwide by the end of 2021 representing 25 nationalities already.
N-SIDE, founded in 2020 by CEO Philippe Chevalier, developed a SaaS platform that helps pharma companies get a more accurate view of future clinical trials, by bringing to bear optimal management of stocks and the distribution network
N-SIDE estimates its 2021 turnover to be €20 million, up by more than 40%;